IDIsabelle Denjoy

Isabelle Denjoy

*This is an algorithmically generated author record based on publicly available information.

Isabelle Denjoy has a total of 423 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nationwide Functional Profiling Enables Clinical Reclassification of KCNH2 Variants in the French LQT2 Population

    by Barbara Ribeiro de Oliveira, Malak Alameh, Sylvain Feliciangeli, Jérôme Montnach, Brieuc Quemeneur, Thomas Gabillon, Nawel Aoujaj, Aline Rio, Floriane Bibault, Elea Lecointe, et al.

    Background: The increasing use of genetic testing has identified thousands of KCNH2 variants associated with long QT syndrome type 2 (LQT2), yet most remain variants of uncertain significance (VUS). Translating functional abnormalities into clinically actionable evidence remains a major challenge. We established a nationwide functional genomics strategy to systematically characterize KCNH2 variants identified in the French LQT2 population and improve their clinical interpretation. Methods: We characterized 303 KCNH2 variants, including 201 VUS, using standardized high-throughput automated patch-clamp electrophysiology and complementary membrane trafficking assays. Nine electrophysiological parameters were integrated using MeTAL to predict variant-specific repolarization phenotypes under homozygous and heterozygous conditions. Modeled QTc values were compared with patient electrocardiographic data and variant-specific penetrance estimates. Functional evidence was calibrated against established benign and pathogenic variants using ClinGen-recommended categorical OddsPath and continuous likelihood-ratio approaches. Results: Multidimensional functional profiling revealed abnormalities not captured by current amplitude alone, identifying additional variants with clinically relevant repolarization defects. Among variants assessed under heterozygous conditions, MeTAL predictions showed 82.9% concordance with patient QTc phenotypes for ACMG class 5 variants, with apparent discordances partly consistent with incomplete penetrance. Continuous likelihood-ratio calibration demonstrated strong discrimination between established benign and pathogenic variants (AUC=0.936) and provided graded functional evidence for 76.1% of VUS. Integration of calibrated functional evidence into the ACMG/AMP framework enabled reclassification of 64 of 201 VUS (31.8%), including 7 as pathogenic, 46 as likely pathogenic, and 11 as likely benign. Conclusions: This nationwide study establishes a scalable framework integrating high-throughput electrophysiology, computational modeling, and clinical phenotyping to translate complex KCNH2 channel dysfunction into clinically interpretable evidence. The resulting reclassification of nearly one-third of VUS, together with the open-access HAMMER database, provides a resource to improve molecular diagnosis and risk assessment in LQT2.

  • Open Access

    Ventricular conduction is a marker for arrhythmic risk in SCN5A- E1784K overlap sodium channel disease

    by Michael W T Tanck, Yanushi D Wijeyeratne, Julien Barc, Alison Muir, Takeshi Aiba, J Martijn Bos, Christian Veltmann, Joseph Galvin, Lia Crotti, Taisuke Ishikawa, et al.

    SCN5A-E1784K (c.5350G>A) is the most common variant associated with the long QT (LQTS) and Brugada syndromes (BrS). It can manifest variably as LQTS, BrS and/or conduction disorders. This presents a challenge for risk stratification. We aimed to describe clinical and ECG characteristics and identify risk markers that associate with arrhythmic events. We undertook a retrospective observational multicentre study of a large cohort of 231 subjects with SCN5A-E1784K from Europe, USA and Japan. Comprehensive demographic and clinical data, including initial presentation ECG and follow-up, were collected. ‘Lethal events’ were defined as sudden death, non-fatal cardiac arrest, and documented sustained VT or VF. ‘Cardiac events’ were defined as arrhythmic syncope plus any lethal events. Clinical characteristics and ECG parameters corrected for age were investigated for association with lethal and/or cardiac events. Fourteen (6%) subjects experienced a lethal event and 45 (19%) a cardiac event. PR interval and QRS duration were associated with lethal and cardiac events. In multivariable models, both PR interval and QRS duration were associated with lethal events but only QRS duration was associated with cardiac events. Only age-corrected QRS (rQRS) was associated with lethal and cardiac event-free survival from birth after correction for multiple testing. Ventricular myocardial conduction appears likely to play a role in the risk of arrhythmic events in patients with SCN5A-E1784K. This provides an important opportunity for the personalisation of management and has the potential to guide preventative therapies.

  • Open Access

    MeTAL enables multiparametric risk prediction for human KCNH2 variants

    by Barbara Ribeiro de Oliveira, Elouan Voisin, Maxence Marbouty, Achille Gregoire, Malak Alameh, Jérôme Montnach, Aurélie Thollet, Flavien Charpentier, Isabelle Denjoy, Vincent Probst, et al.

    Background: Clinical interpretation of missense variants in the hERG potassium channel encoded by the KCNH2 gene remains a major challenge in inherited arrhythmia syndromes. Functional studies often rely on a minimal set of channel properties, mainly current amplitude measurements, which do not capture the multidimensional nature of channel gating and its impact on ventricular repolarization. We developed a multiscale computational framework to quantitatively link multiparametric channel dysfunction to ECG phenotypes. Methods: We generated multiparametric electrophysiological profiles for KCNH2 variants using high-throughput patch-clamp, quantifying nine biophysical properties including conductance, voltage dependence, and gating kinetics. These parameters were incorporated into a modified formulation of I Kr embedded in a human ventricular electrophysiology model. The resulting framework, termed MeTAL (Multiscale-enriched Transformation and Analysis for Long-QT), produces physiologically calibrated pseudo-ECGs enabling quantitative evaluation of QT dynamics. We systematically analyzed the contribution of individual and combined gating parameters and applied the model to 41 KCNH2 variants across ACMG classes, comparing simulated QTc values with clinical data. Results: Multiparametric profiling revealed complex functional signatures in most variants, with concurrent gain- and loss-of-function effects affecting distinct gating processes. Simulations demonstrated that ventricular repolarization, though strongly determined by current amplitude, is substantially influenced by inactivation-related parameters, particularly the slope and voltage dependence of inactivation. Interaction analyses showed nonlinear relationships between gating parameters, explaining why variants with similar current density can produce divergent QT phenotypes. In heterozygous simulations, MeTAL reproduced clinically observed QTc distributions across variant classes and accurately predicted the repolarization regime (normal, long-QT, or short-QT) in most cases. Conclusions: Multiparametric integration of ion-channel function within a multiscale electrophysiological model enables mechanistic prediction of QT behavior beyond conductance-based metrics. This approach provides a scalable framework for interpretation of KCNH2 variants and solves the issue of risk stratification in inherited arrhythmia syndromes while offering new opportunities for variant-specific and pharmacological modeling of repolarization.


  • Open Access

    Clinical profile and prognosis of brugada syndrome SCN5A variant carriers with negative sodium channel blocker challenge

    by Elodie Surget, Gael Clerici, Frédéric Sacher, Raphael Martins, Philippe Maury, Isabelle Denjoy, Aurélie Thollet, Julien Barc, Jean Jacques Schott, Nathalie Drapier, et al.

    Loss-of-function (LOF) variants in SCN5A are associated with Brugada syndrome (BrS), progressive conduction slowing, and other arrhythmias. While the prognosis of SCN5A carriers with a positive sodium channel blocker challenge (SCBC) is established, data on those with negative SCBC are limited. To assess the clinical presentation and prognosis of SCN5A variant carriers with negative SCBC, and compare them to relatives with positive SCBC. We retrospectively included patients from five university hospitals (2000–2024) carrying a pathogenic or likely pathogenic SCN5A variant and negative SCBC. Relatives with the same variant and positive SCBC were also analysed. Patients with spontaneous type 1 ECG, gain-of-function variants, double variants, or ACMG class 1–3 variants were excluded. Clinical, ECG, genetic, and follow-up data were collected. Conduction slowing was evaluated using the PR interval and QRS duration. The cohort included 162 patients from 43 families (median age 37 ± 19 years, 46% male), of whom 69 (43%) had negative SCBC. Among these 69 patients, 25 (36%) had baseline intraventricular conduction defects, and 19 (28%) had first-degree AV block. After a median follow-up of 75 [40–168] months, 52% of patients developed progressive conduction slowing. Negative SCBC patients had fewer conduction defects (36% vs. 70%, p = 0.002) and ICD implantations (1% vs. 23%, P < 0.001). Non-missense variants were associated with more conduction slowing (71% vs. 42%, P = 0.04). This multicentre study provides the largest analysis of SCN5A carriers with negative SCBC, showing excellent arrhythmic prognosis despite frequent progressive conduction slowing.


  • Open Access

    SPARC: a structural pathogenicity algorithm for risk classification of hERG variants

    by Frank C Chatelain, Barbara Ribeiro de Oliveira, Guillaume Grataloup, Noé Robert, Malak Alameh, Aurélie Thollet, Jérôme Montnach, Sylvain Feliciangeli, Aline Rio, Floriane Bibault, et al.

    Inherited mutations in the KCNH2 gene, which encodes the cardiac hERG potassium channel, are major contributors to arrhythmogenic syndromes such as long QT and short QT syndromes. However, clinical interpretation of the growing number of missense variants – many of which are classified as variants of uncertain significance (VUS) – remains a pressing challenge. Here, we present a semi-automated in silico pipeline for predicting hERG variant pathogenicity, acting as a binary classifier and integrating five structural metrics – residue volume, hydrophobicity, charge, steric clashes, and proximity to pathogenic hotspots – into a composite structural pathogenicity score (SPS) scaled from 1 to 5. Applied to 1727 hERG variants from ClinVar and from a French nationwide cohort, this binary classifier, termed SPARC, identified 260 variants as high risk of pathogenicity with SPS ≥3.25, of which a representative subset from the French cohort was functionally validated using high-throughput automated patch-clamp. Functional phenotyping confirmed the structural predictions, including for several VUS, demonstrating that comprehensive structural scoring can reliably stratify variant pathogenicity. This approach, benchmarked with Alpha Missense and Revel, offers a superior scalable, cost-effective pre-screening tool to guide clinical variant interpretation and prioritization for experimental validation.


  • Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification

    by Krystien V Lieve, Christian van der Werf, Dania Kallas, Isabelle Denjoy, J Martijn Bos, Takeshi Aiba, Elijah R Behr, Maarten P van Den Berg, Auke T Bergeman, Nico A Blom, et al.

    Background and Aims: Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for potentially life-threatening arrhythmic events (AEs) even while treated with β-blockers. The aim was to develop a model for individualized prediction of AEs in patients with RYR2-mediated CPVT on β-blocker monotherapy. Methods: The derivation and independent validation cohorts included 743 and 129 patients, respectively. AEs were defined as arrhythmic syncope, appropriate implantable cardioverter–defibrillator shock, sudden cardiac arrest (SCA), and sudden cardiac death. Near-fatal or fatal AEs (nf/fAEs) included all AEs except for arrhythmic syncope. Prediction models using Cox regression were developed and internally and externally validated. Results: A total of 102 (13.7%) patients in the derivation cohort and 24 (18.6%) patients in the validation cohort experienced ≥1 AE over a median follow-up of 5.1 [interquartile range (IQR), 7.7] and 2.4 (IQR, 4.4) years, respectively. Predictors of AE were arrhythmic syncope or SCA prior to diagnosis and age at β-blocker initiation. In the derivation and validation cohorts, the optimism-corrected C-indices of the models for AE were 0.67 [95% confidence interval (CI) 0.62–0.72] and 0.59 (95% CI 0.48–0.71), respectively. For nf/fAEs, ventricular arrhythmia severity before β-blocker initiation was a fourth independent predictor, and C-indices of the models in the derivation and validation cohorts were 0.74 (95% CI 0.68–0.80) and 0.60 (95% CI 0.47–0.72), respectively. In the derivation cohort, calibration slopes were 1.00 (95% CI 0.59–1.41) for AE and 1.00 (95% CI 0.69–1.32) for nf/fAE. Conclusions: These externally validated risk prediction models using clinical parameters accurately distinguished CPVT patients on β-blocker monotherapy at low and high risk for future AEs while treated with β-blockers. These models provide guidance for implementation of clinical management therapies to prevent AEs in patients with CPVT.


  • Open Access

    Distinct patterns of ventricular fibrillation onset in primary electrical diseases: insights from a retrospective multicentre registry

    by Elodie Surget, Wally Wences Mansogo, Alessandra Pia Porretta, Constance Beyler, Adrien Bloch, Isabelle Denjoy, Michel Haissaguerre, Fabrice Extramiana

    Aims: Ventricular fibrillation (VF) initiation is influenced by the underlying arrhythmia mechanism. Long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), Brugada syndrome (BS), and idiopathic ventricular fibrillation (IVF) share overlapping clinical features that often hamper their diagnosis. This study aims to identify distinctive features of VF pattern that may provide additional diagnostic tools to discriminate them. Methods and results: We included consecutive patients affected by LQTS, CPVT, BS, or IVF with recurrent VF episodes. The evaluation of VF episodes documented on electrocardiogram or implantable cardioverter-defibrillator recordings allowed us to assess different features of VF episodes including sinus rhythm preceding VF, the trigger’s coupling interval (CI) initiating VF, and the mean cycle length of VF (VFCL) of the 10 first VF beats. Among 2399 patients with LQTS (n = 1587), CPVT (n = 155), BS (n = 584), or IVF (n = 62), 76 episodes of VF were identified in 30 patients. Catecholaminergic polymorphic ventricular tachycardia patients presented higher heart rate preceding VF (CL = 359 ± 26 ms; P < 0.001) and shorter trigger’s CI initiating VF (256 ± 21 ms; P < 0.001). Short-long-short sequence and very long CI (>450 ms) of trigger initiating VF were mostly observed in LQTS (54%; P < 0.001 and 68%, respectively). The VFCL was shorter in CPVT patients (168 ± 15 ms; P < 0.001). Based on these results, we created a discrimination algorithm to support the diagnostic process in clinical practice. Conclusion: Primary electrical diseases display distinct VF patterns. The comprehensive analysis of VF pattern, rather than of isolated VF features, holds then a major potential to support diagnostic accuracy and consequently refine therapeutic strategies in patients and in their relatives.


  • Open Access

    Software-based analysis of T-wave morphology: identifying the electrocardiogram signature of high-risk long QT syndrome

    by Alessandra Pia Porretta, Charles Morgat, Elodie Surget, Véronique Fressart, Adrien Bloch, Nathalie Neyroud, Fabio Badilini, Martino Vaglio, Isabelle Denjoy, Fabrice Extramiana

    Aims: Despite T-wave morphology abnormalities being well-known distinctive ECG features in patients with long QT syndrome (LQTS), the subjectivity of qualitative ‘eyeballing’ in T-wave characterization still hampers its integration into diagnostic/prognostic criteria. We herein evaluated whether our quantitative software-based analysis of T-wave morphology (AnTwM) applied to digital ECGs may identify predictors of cardiac events (CEs) in our cohort of LQTS patients. Methods and results: We enrolled LQT1, LQT2, and LQT3 patients having at least one digital ECG from our cohort of genotype-confirmed LQTS patients. Automated AnTwM analysis, using Glasgow and Bravo algorithms embedded in the CalECG software (AMPS-IIc, USA), provided scalar descriptors of ventricular repolarization. Cox regression analyses identified potential predictors of CEs (i.e. syncope, sudden cardiac death, resuscitated cardiac arrest, or appropriate shock delivered by implantable cardioverter defibrillators). A total of 467 (58% female) patients were followed up for 15 ± 9 years, including 253 (54.2%) LQT1, 182 (39%) LQT2, and 32 (6.8%) LQT3 patients. Corrected QT interval predicted CEs in the whole population (1 ms QTc increase: HR = 1.01, 95% CI: 1.0–1.01, P = 0.03) but not across genotyped subpopulations. Genotype-specific ECG markers associated with a greater risk of CEs were (i) those expressing a delayed accumulation of the mid-late T-wave area (decreased t25 and increased t50) among LQT1 patients and (ii) those expressing T-wave flattening/widening (decreased T-wave ascending/descending slopes) among LQT2 patients. Conclusion: The software-based AnTwM on digital ECGs represented a reliable tool in clinical practice and identified unique ECG T-wave ‘fingerprints’ that allowed prediction of CEs in a genotype-specific manner.


  • Open Access

    Genetic characterization of KCNQ1 variants improves risk stratification in type 1 long QT syndrome patients

    by Charles Morgat, VérOnique Fressart, Alessandra Pia Porretta, Nathalie Neyroud, Anne Messali, Yassine Temmar, Vincent Algalarrondo, Elodie Surget, Adrien Bloch, Antoine Leenhardt, et al.

    KCNQ1 mutations cause QTc prolongation increasing life-threatening arrhythmias risks. Heterozygous mutations [type 1 long QT syndrome (LQT1)] are common. Homozygous KCNQ1 mutations cause type 1 Jervell and Lange–Nielsen syndrome (JLNS) with deafness and higher sudden cardiac death risk. KCNQ1 variants causing JLNS or LQT1 might have distinct phenotypic expressions in heterozygous patients. The aim of this study is to evaluate QTc duration and incidence of long QT syndrome–related cardiac events according to genetic presentation. We enrolled LQT1 or JLNS patients with class IV/V KCNQ1 variants from our inherited arrhythmia clinic (September 1993 to January 2023). Medical history, ECG, and follow-up were collected. Additionally, we conducted a thorough literature review for JLNS variants. Survival curves were compared between groups, and multivariate Cox regression models identified genetic and clinical risk factors. Among the 789 KCNQ1 variant carriers, 3 groups were identified: 30 JLNS, 161 heterozygous carriers of JLNS variants (HTZ-JLNS), and 550 LQT1 heterozygous carriers of non-JLNS variants (HTZ-Non-JLNS). At diagnosis, mean age was 3.4 ± 4.7 years for JLNS, 26.7 ± 21 years for HTZ-JLNS, and 26 ± 21 years for HTZ-non-JLNS; 55.3% were female; and the mean QTc was 551 ± 54 ms for JLNS, 441 ± 32 ms for HTZ-JLNS, and 467 ± 36 ms for HTZ-Non-JLNS. Patients with heterozygous JLNS mutations (HTZ-JLNS) represented 22% of heterozygous KCNQ1 variant carriers and had a lower risk of cardiac events than heterozygous non-JLNS variant carriers (HTZ-Non-JLNS) [hazard ratio (HR) = 0.34 (0.22–0.54); P < 0.01]. After multivariate analysis, four genetic parameters were independently associated with events: haploinsufficiency [HR = 0.60 (0.37–0.97); P = 0.04], pore localization [HR = 1.61 (1.14–1.2.26); P < 0.01], C-terminal localization [HR = 0.67 (0.46–0.98); P = 0.04], and group [HR = 0.43 (0.27–0.69); P < 0.01]. Heterozygous carriers of JLNS variants have a lower risk of cardiac arrhythmic events than other LQT1 patients.


  • Open Access

    Insights into adherence to medication and lifestyle recommendations in an international cohort of patients with catecholaminergic polymorphic ventricular tachycardia

    by Puck J Peltenburg, Lieke M van Den Heuvel, Dania Kallas, Cheyanne Bell, Isabelle Denjoy, Elijah R Behr, Ella Field, Janneke A E Kammeraad, Sing-Chien Yap, Vincent Probst, et al.

    In patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare inherited arrhythmia syndrome, arrhythmic events can be prevented by medication and lifestyle recommendations. In patients who experience breakthrough arrhythmic events, non-adherence plays an essential role. We aimed to investigate the incidence and potential reasons for non-adherence to medication and lifestyle recommendations in a large, international cohort of patients with CPVT. An online multilingual survey was shared with CPVT patients worldwide by their cardiologists, through peer-recruitment, and on social media from November 2022 until July 2023. Self-reported non-adherence was measured using the validated Medication Adherence Rating Scale (MARS) and a newly developed questionnaire about lifestyle. Additionally, validated questionnaires were used to assess potential reasons for medication non-adherence. Two-hundred-and-eighteen patients completed the survey, of whom 200 (92%) were prescribed medication [122 (61%) female; median age 33.5 years (interquartile range: 22–50)]. One-hundred-and-three (52%) were prescribed beta-blocker and flecainide, 85 (43%) beta-blocker, and 11 (6%) flecainide. Thirty-four (17%) patients experienced a syncope, aborted cardiac arrest or appropriate implantable cardioverter defibrillator shock after diagnosis. Nineteen (13.4%) patients were exercising more than recommended. Thirty (15%) patients were non-adherent to medication. Female sex [odds ratio (OR) 3.7, 95% confidence interval (CI) 1.3–12.0, P = 0.019], flecainide monotherapy compared to combination therapy (OR 6.8, 95% CI 1.6–31.0, P = 0.010), and a higher agreement with statements regarding concerns about CPVT medication (OR 1.2, 95% CI 1.1–1.3, P < 0.001) were independently associated with non-adherence. The significant rate of non-adherence associated with concerns regarding CPVT-related medication, emphasizes the potential for improving therapy adherence by targeted patient education.